share_log

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga ·  Apr 30 04:31

Gainers

  • GeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings came out today.
  • InnovAge Holding (NASDAQ:INNV) shares increased by 7.25% to $3.99. The market value of their outstanding shares is at $542.2 million.
  • Mustang Bio (NASDAQ:MBIO) shares increased by 5.48% to $0.25. The market value of their outstanding shares is at $2.5 million.
  • Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 5.23% to $0.79. The market value of their outstanding shares is at $38.1 million.
  • Seelos Therapeutics (NASDAQ:SEEL) shares increased by 4.88% to $0.29. The market value of their outstanding shares is at $4.0 million.
  • NewAmsterdam Pharma (NASDAQ:NAMS) shares increased by 4.8% to $22.7. The market value of their outstanding shares is at $2.0 billion.

Losers

  • GlucoTrack (NASDAQ:GCTK) stock declined by 10.7% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $13.3 million.
  • Vaxxinity (NASDAQ:VAXX) stock decreased by 9.44% to $0.14. The company's market cap stands at $18.1 million.
  • Ekso Bionics Holdings (NASDAQ:EKSO) stock fell 5.43% to $1.22. The market value of their outstanding shares is at $21.8 million. As per the press release, Q1 earnings came out today.
  • Cosmos Health (NASDAQ:COSM) shares declined by 5.0% to $0.67. The company's market cap stands at $11.3 million.
  • Inozyme Pharma (NASDAQ:INZY) stock decreased by 4.98% to $4.2. The market value of their outstanding shares is at $259.4 million.
  • Prenetics Global (NASDAQ:PRE) shares fell 4.73% to $4.24. The market value of their outstanding shares is at $51.7 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment